When to Prescribe Controller Inhalers in Adults with Asthma
All adults with asthma should receive inhaled corticosteroid (ICS)-containing medication and should never be treated with short-acting beta-agonist (SABA) alone 1, 2.
Core Recommendation
The paradigm has fundamentally shifted: controller therapy with ICS is indicated for ALL adults with asthma, regardless of symptom frequency or severity 1, 2. The outdated approach of waiting until symptoms occur more than 2 days per week has been abandoned based on evidence showing equal benefit across all symptom frequencies 3.
Specific Clinical Scenarios
Mild Persistent Asthma (Adults ≥12 years)
For adults with mild persistent asthma, you have two evidence-based options 4:
- Option 1: Daily low-dose ICS + as-needed SABA
- Option 2: As-needed ICS and SABA used concomitantly (anti-inflammatory reliever approach)
The 2024 GINA guidelines now prefer Track 1 using low-dose ICS-formoterol as an anti-inflammatory reliever (AIR), either as-needed-only or as maintenance-and-reliever therapy (MART), because it substantially reduces severe exacerbations compared to SABA-based regimens 1, 2.
Moderate to Severe Persistent Asthma (Adults ≥12 years)
For moderate to severe persistent asthma, strongly recommend ICS-formoterol in a single inhaler used as both daily controller and reliever therapy 4. This approach has high certainty of evidence and is superior to:
- Higher-dose ICS as daily controller with SABA for quick-relief
- Same-dose ICS-LABA as daily controller with SABA for quick-relief
Critical Evidence Supporting Early Initiation
The START study definitively demonstrated that low-dose ICS reduces severe asthma-related events (hospitalizations, emergency treatment, death) equally across all symptom frequency subgroups 3:
- 0-1 symptom days/week: 46% reduction (HR 0.54)
1 to ≤2 symptom days/week: 40% reduction (HR 0.60)
2 symptom days/week: 43% reduction (HR 0.57)
There was no statistical interaction by symptom frequency (p=0.94), meaning the protective effect is consistent regardless of how often symptoms occur 3.
Timing Matters
Initiate ICS as soon as asthma is diagnosed 5, 6. "Early intervention" means starting ICS within 2 years of symptom onset, not from diagnosis date 5. Benefits include:
- Rapid symptom reduction (within 24 hours) 6
- Early achievement of asthma control 5
- Prevention of lung function decline 3
- Reduced exacerbation risk 3
Delaying ICS therapy exposes patients to unnecessary morbidity and may delay asthma control, though it doesn't necessarily reduce long-term effectiveness on lung function 5.
Common Pitfalls to Avoid
Never prescribe SABA monotherapy - This is explicitly recommended against by current guidelines 1, 2. SABA-only treatment increases exacerbation risk and mortality.
Don't wait for "persistent" symptoms - The traditional cutoff of >2 symptom days per week lacks evidence and should not guide ICS initiation 3. Even patients with infrequent symptoms benefit equally from ICS therapy.
Don't recommend short-term ICS dose increases for symptom worsening - In patients aged 4+ years with mild-moderate persistent asthma who are adherent to daily ICS, the guidelines conditionally recommend against temporarily increasing ICS doses for increased symptoms or decreased peak flow 4.
Practical Implementation
Start with low-dose ICS for most patients - this is cost-effective, safe, and achieves control in most cases 7, 6. Reserve higher doses for uncontrolled disease, and consider adding long-acting beta-agonists (LABA) or moving to ICS-formoterol MART regimens before escalating to high-dose ICS to minimize systemic adverse effects 8.
For patients reluctant to use daily ICS long-term, the as-needed ICS-formoterol approach provides a reasonable alternative that maintains anti-inflammatory protection while reducing treatment burden 1, 9, 2.